Completed PHASE3 INTERVENTIONAL 2-arm NCT00280969

Comparing the Effectiveness Between Ritonavir Boosted Atazanavir and Efavirenz for the First HIV Treatment

Open-label Randomized Multicenter Study of Once Daily Antiretroviral Treatment Regimen Comparing Ritonavir Boosted Atazanavir to Efavirenz

Sponsor: International Medical Center of Japan

Conditions HIV Infection

Interventions atazanavir arm efavirenz

Updated 5 times since 2017 Last updated: Mar 27, 2015 Started: Sep 30, 2005 Primary completion: Sep 30, 2009 Completion: Sep 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on HIV Infection, this trial is completed. The trial is conducted by International Medical Center of Japan and has accumulated 5 data snapshots since 2005. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

International Medical Center of Japan
Ministry of Health, Labour and Welfare, Japan

Data source: International Medical Center of Japan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shinjuku, Japan